These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10320042)

  • 1. Herpes simplex virus latency and nucleoside analogues.
    Efstathiou S; Field HJ; Griffiths PD; Kern ER; Sacks SL; Sawtell NM; Stanberry LR
    Antiviral Res; 1999 Apr; 41(3):85-100. PubMed ID: 10320042
    [No Abstract]   [Full Text] [Related]  

  • 2. Early therapy with valaciclovir or famciclovir reduces but does not abrogate herpes simplex virus neuronal latency.
    Field HJ; Thackray AM
    Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):461-70. PubMed ID: 10772727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can HSV latency be conquered by current antiviral therapies?
    Simmons A; Field HJ
    Sex Transm Infect; 1998 Feb; 74(1):1-2. PubMed ID: 9634293
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of acyclovir-resistant herpes simplex and varicella zoster virus infections.
    Safrin S
    Adv Exp Med Biol; 1996; 394():59-66. PubMed ID: 8815710
    [No Abstract]   [Full Text] [Related]  

  • 5. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.
    Bacon TH; Levin MJ; Leary JJ; Sarisky RT; Sutton D
    Clin Microbiol Rev; 2003 Jan; 16(1):114-28. PubMed ID: 12525428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo.
    Sawtell NM; Thompson RL; Stanberry LR; Bernstein DI
    J Infect Dis; 2001 Oct; 184(8):964-71. PubMed ID: 11574910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice: how dissimilar are study results?
    Thackray AM; Field HJ
    J Infect Dis; 2000 Apr; 181(4):1517-8. PubMed ID: 10762588
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of therapeutic drug monitoring in the long-term valaciclovir therapy of relapsing herpes simplex virus encephalitis in children.
    Lim M; Menson E; Tong CY; Lin JP
    J Antimicrob Chemother; 2009 Dec; 64(6):1340-1. PubMed ID: 19828489
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical utility of susceptibility testing of herpes simplex virus to acyclovir].
    Otegui M; Rabella N; Labeaga R; Herrero M; Margall N; Muñoz JM; Prats G
    Rev Esp Quimioter; 2001 Dec; 14(4):351-7. PubMed ID: 11856981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors and outcomes of acyclovir-resistant herpes simplex virus infection among hematopoietic cell transplant recipients: case-case-control investigation.
    Patel D; Marchaim D; Marcus G; Gayathri R; Lephart PR; Lazarovitch T; Zaidenstein R; Chandrasekar P
    Clin Transplant; 2014 Jan; 28(1):1-5. PubMed ID: 24033498
    [No Abstract]   [Full Text] [Related]  

  • 11. A quantitative study of the effects of several nucleoside analogues on established herpes encephalitis in mice.
    Field HJ; Anderson JR; Efstathiou S
    J Gen Virol; 1984 Apr; 65 ( Pt 4)():707-19. PubMed ID: 6323620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are we too cavalier about antiviral prophylaxis?
    Onwudiwe OC; Marmur ES; Cohen JL
    J Drugs Dermatol; 2013 Feb; 12(2):199-205. PubMed ID: 23377394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anti-HSV therapeutics target the helicase-primase complex.
    Crumpacker CS; Schaffer PA
    Nat Med; 2002 Apr; 8(4):327-8. PubMed ID: 11927930
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of herpes simplex virus infection and latency by prophylactic treatment with acyclovir in a weanling mouse model.
    Dobson AT; Little BB; Scott LL
    Am J Obstet Gynecol; 1998 Aug; 179(2):527-32. PubMed ID: 9731864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis.
    Taskintuna I; Banker AS; Flores-Aguilar M; Bergeron-Lynn G; Aldern KA; Hostetler KY; Freeman WR
    Retina; 1997; 17(1):57-64. PubMed ID: 9051844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.
    James SH; Prichard MN
    Curr Opin Virol; 2014 Oct; 8():54-61. PubMed ID: 25036916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic implications of new insights into the critical role of VP16 in initiating the earliest stages of HSV reactivation from latency.
    Thompson RL; Sawtell NM
    Future Med Chem; 2010 Jul; 2(7):1099-105. PubMed ID: 21426158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyclovir suppresses subclinical shedding of herpes simplex virus.
    Straus SE; Rooney JF; Hallahan C
    Ann Intern Med; 1996 Nov; 125(9):776-7. PubMed ID: 8929015
    [No Abstract]   [Full Text] [Related]  

  • 19. Problems of herpes simplex virus latency.
    Klein RJ
    Antiviral Res; 1985; Suppl 1():111-20. PubMed ID: 3002250
    [No Abstract]   [Full Text] [Related]  

  • 20. [ESOPHAGITIS, CAUSED BY HERPES SIMPLEX VIRUS: CASE REPORT].
    Butorin NN; Tsukanov VV; Vasjutin AV; Reznikova OS; Vershinina GR; Kim MA
    Eksp Klin Gastroenterol; 2015; (4):94-7. PubMed ID: 26415273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.